Research programme: CNS disorder liposomal therapeutics - Sihuan/BBB TherapeuticsAlternative Names: Glutathione-pegylated liposomal therapeutics - Sihuan/to-BBB
Latest Information Update: 03 Oct 2014
At a glance
- Originator Sihuan Pharmaceutical Holdings Group; to-BBB technologies
- Developer BBB Therapeutics; Sihuan Pharmaceutical Holdings Group
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Research CNS disorders
Most Recent Events
- 30 Sep 2014 to-BBB technologies is now called BBB Therapeutics
- 12 Feb 2014 Profile released, added ADMN.
- 11 Dec 2013 Early research in CNS disorders in China (Parenteral)